Table 3.
Variables |
Total
(n = 581) |
No DND
(n = 556) |
DND
(n = 25) |
P | Good 3-month outcome (n = 391) | Poor 3-month outcome (n = 190) | P |
---|---|---|---|---|---|---|---|
Age, years, median (IQR) | 61 (53-69) | 61(53-69) | 65 (52-72.5) | 0.349 | 60 (52-68) | 63 (54-71) | 0.007 |
Sex (male), n (%) | 423 (72.8) | 406 (73) | 17 (68) | 0.581 | 283 (72.4) | 140 (73.7) | 0.74 |
Current smoking, n (%) | 326 (56.1) | 313 (56.3) | 13 (52) | 0.672 | 226 (57.8) | 100 (52.6) | 0.239 |
Current drinking, n (%) | 253 (43.5) | 245 (44.1) | 8 (32) | 0.234 | 171 (43.7) | 82 (43.2) | 0.895 |
Atrial fibrillation, n (%) | 27 (4.6) | 24 (4.3) | 3 (12) | 0.074 | 20 (5.1) | 7 (3.7) | 0.442 |
Coronary artery disease, n (%) |
116 (20) | 110 (19.8) | 6 (24) | 0.606 | 75 (19.2) | 41 (21.6) | 0.498 |
Diabetes, n (%) | 189 (32.5) | 175 (31.5) | 14 (56) | 0.01 | 117 (29.9) | 72 (37.9) | 0.054 |
Hypertension, n (%) | 302 (52) | 283 (50.9) | 19 (76) | 0.014 | 190 (48.6) | 112 (58.9) | 0.019 |
Time from stroke onset to IVT infusion (min), median (IQR) | 180 (141-230) | 180 (141-228.75) | 175 (146.5-239) | 0.674 | 182 (144-231) | 175 (134.75-230) | 0.138 |
Prior stroke, n (%) | 88 (15.1) | 84 (15.1) | 4 (16) | 0.903 | 52 (13.3) | 36 (18.9) | 0.075 |
Systolic blood pressure, mmHg, median (IQR) | 154 (138-165) | 154 (138-165) | 160 (144-167) | 0.589 | 152 (138-164) | 157 (142-169) | 0.009 |
Diastolic blood pressure, mmHg, median (IQR) | 89 (80-98) | 89 (80-98) | 92 (82.5-99.5) | 0.649 | 89 (80-98) | 89 (81-98) | 0.599 |
Antihypertensive therapy, n (%) |
200 (34.4) | 188 (33.8) | 12 (48) | 0.144 | 124 (31.7) | 76 (40) | 0.049 |
Antiplatelet therapy, n (%) | 73 (12.6) | 68 (12.2) | 5 (20) | 0.252 | 45 (11.5) | 28 (14.7) | 0.271 |
Hypoglycemic therapy, n (%) | 102 (17.6) | 95 (17.1) | 7 (28) | 0.161 | 65 (16.6) | 37 (19.5) | 0.397 |
Baseline blood glucose, mmol/L, median (IQR) | 6.92 (6.13-8.65) | 6.88 (6.08-8.64) | 7.27 (6.6-9.37) | 0.166 | 6.8 (6.02-8.62) | 7.12 (6.28-8.72) | 0.154 |
Baseline NIHSS score, median (IQR) |
9 (5-13) | 9 (5-12) | 14 (9-19) | 0.002 | 8 (4-11) | 12 (8-15) | <0.01 |
Baseline neutrophil (109/L), median (IQR) | 5.41 (3.98-7.44) | 5.38 (3.96-7.27) | 8.09 (4.10-10.76) | 0.056 | 5.25 (3.79-7.15) | 5.67 (4.27-8.04) | 0.016 |
Baseline PLT (109/L), median (IQR) |
200 (170-231) | 200.5 (170-231) | 195 (168-232.5) | 0.968 | 197 (170-230) | 203 (170-236) | 0.260 |
Baseline PNR, median (IQR) | 36.71 (26.04-51.29) | 36.82 (26.29-51.37) | 30.77 (17.68-51.04) | 0.118 | 37 (26.57-52.49) | 36.33 (23.96-48.28) | 0.169 |
Post-IVT neutrophil (109/L), median (IQR) | 5.39 (4.23-7.26) | 5.31 (4.20-7.12) | 9.86 (5.60-14.38) | <0.01 | 4.88 (3.87-6.16) | 6.83 (5.29-9.55) | <0.01 |
Post-IVT PLT (109/L), median (IQR) |
205 (173-237) | 205 (173.25-238) | 204 (164.5-228.5) | 0.701 | 204 (172-237) | 208.5 (179-238.75) | 0.249 |
Post-IVT PNR, median (IQR) | 37.76 (27.16-49.33) | 37.81 (28.01-49.51) | 17.18 (13.33-38.58200) | <0.01 | 41.67 (30.97-52.14) | 28.92 (20.89-40.64) | <0.01 |
Abbreviations: DND, Delayed Neurological Deterioration; NIHSS, National Institute of Health Stroke Scale; PLT, Platelet; PNR, Platelet-to-Neutrophil Ratio; IVT, Intravenous Thrombolysis.